CN Patent

CN109663130B — Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途

Assigned to Jiangsu Hengrui Medicine Co Ltd · Expires 2021-06-29 · 5y expired

What this patent protects

本发明涉及PD‑1抗体或其抗原结合片段和MEK抑制剂联合在制备治疗肿瘤的药物中的用途。具体而言，本发明涉及PD‑1抗体或其抗原结合片段和化合物(1)或其可药用盐联合在制备治疗肿瘤的药物中的用途。

USPTO Abstract

本发明涉及PD‑1抗体或其抗原结合片段和MEK抑制剂联合在制备治疗肿瘤的药物中的用途。具体而言，本发明涉及PD‑1抗体或其抗原结合片段和化合物(1)或其可药用盐联合在制备治疗肿瘤的药物中的用途。

Drugs covered by this patent

Patent Metadata

Patent number: CN109663130B
Jurisdiction: CN
Classification: —
Expires: 2021-06-29
Drug substance claim: No
Drug product claim: No
Assignee: Jiangsu Hengrui Medicine Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.